144 related articles for article (PubMed ID: 18007509)
1. Self-organizing neural networks for modeling robust 3D and 4D QSAR: application to dihydrofolate reductase inhibitors.
Polanski J; Bak A; Gieleciak R; Magdziarz T
Molecules; 2004 Dec; 9(12):1148-59. PubMed ID: 18007509
[TBL] [Abstract][Full Text] [Related]
2. Generation of QSAR sets with a self-organizing map.
Guha R; Serra JR; Jurs PC
J Mol Graph Model; 2004 Sep; 23(1):1-14. PubMed ID: 15331049
[TBL] [Abstract][Full Text] [Related]
3. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
4. Prediction of dihydrofolate reductase inhibition and selectivity using computational neural networks and linear discriminant analysis.
Mattioni BE; Jurs PC
J Mol Graph Model; 2003 Mar; 21(5):391-419. PubMed ID: 12543137
[TBL] [Abstract][Full Text] [Related]
5. A DFT-based QSAR study on inhibition of human dihydrofolate reductase.
Karabulut S; Sizochenko N; Orhan A; Leszczynski J
J Mol Graph Model; 2016 Nov; 70():23-29. PubMed ID: 27649548
[TBL] [Abstract][Full Text] [Related]
6. Free energy force field (FEFF) 3D-QSAR analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors.
Santos-Filho OA; Mishra RK; Hopfinger AJ
J Comput Aided Mol Des; 2001 Sep; 15(9):787-810. PubMed ID: 11776291
[TBL] [Abstract][Full Text] [Related]
7. Towards a MIP-based alignment and docking in computer-aided drug design.
Barbany M; Gutiérrez-de-Terán H; Sanz F; Villà-Freixa J
Proteins; 2004 Aug; 56(3):585-94. PubMed ID: 15229890
[TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR Study on dihydro-1,3,5-triazines and their spiro derivatives as DHFR inhibitors by comparative molecular field analysis (CoMFA).
Ma X; Xiang G; Yap CW; Chui WK
Bioorg Med Chem Lett; 2012 May; 22(9):3194-7. PubMed ID: 22483391
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V + S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme.
Adane L; Bharatam PV
J Mol Graph Model; 2009 Nov; 28(4):357-67. PubMed ID: 19796975
[TBL] [Abstract][Full Text] [Related]
10. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
[TBL] [Abstract][Full Text] [Related]
11. QSAR using evolved neural networks for the inhibition of mutant PfDHFR by pyrimethamine derivatives.
Hecht D; Cheung M; Fogel GB
Biosystems; 2008 Apr; 92(1):10-5. PubMed ID: 18160210
[TBL] [Abstract][Full Text] [Related]
12. Quantitative structure-activity relationships by evolved neural networks for the inhibition of dihydrofolate reductase by pyrimidines.
Landavazo DG; Fogel GB; Fogel DB
Biosystems; 2002 Feb; 65(1):37-47. PubMed ID: 11888662
[TBL] [Abstract][Full Text] [Related]
13. CoMFA/CoMSIA 3D-QSAR of pyrimidine inhibitors of Pneumocystis carinii dihydrofolate reductase.
Santos-Filho OA; Forge D; Hoelz LV; de Freitas GB; Marinho TO; Araújo JQ; Albuquerque MG; de Alencastro RB; Boechat N
J Mol Model; 2012 Sep; 18(9):4061-72. PubMed ID: 22527273
[TBL] [Abstract][Full Text] [Related]
14. The structure-based design and synthesis of selective inhibitors of Trypanosoma cruzi dihydrofolate reductase.
Zuccotto F; Brun R; Gonzalez Pacanowska D; Ruiz Perez LM; Gilbert IH
Bioorg Med Chem Lett; 1999 May; 9(10):1463-8. PubMed ID: 10360757
[TBL] [Abstract][Full Text] [Related]
15. Solution of the conformation and alignment tensors for the binding of trimethoprim and its analogs to dihydrofolate reductase: 3D-quantitative structure-activity relationship study using molecular shape analysis, 3-way partial least-squares regression, and 3-way factor analysis.
Dunn WJ; Hopfinger AJ; Catana C; Duraiswami C
J Med Chem; 1996 Nov; 39(24):4825-32. PubMed ID: 8941396
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR studies on the inhibitory activity of trimethoprim analogues against Escherichia coli dihydrofolate reductase.
Vijayaraj R; Devi ML; Subramanian V; Chattaraj PK
Chem Biol Drug Des; 2012 Jun; 79(6):935-42. PubMed ID: 22304783
[TBL] [Abstract][Full Text] [Related]
17. Investigating the selectivity of potential new inhibitors of dihydrofolate reductase from Yersinia pestis designed by molecular modeling.
Bastos LDC; de Souza FR; Pereira Souza LM; Forgione P; Cuya T; de Alencastro RB; Pimentel AS; Celmar Costa França T
J Biomol Struct Dyn; 2019 Mar; 37(5):1170-1176. PubMed ID: 29542379
[No Abstract] [Full Text] [Related]
18. CoMFA and CoMSIA analyses of Pneumocystis carinii dihydrofolate reductase, Toxoplasma gondii dihydrofolate reductase, and rat liver dihydrofolate reductase.
Gangjee A; Lin X
J Med Chem; 2005 Mar; 48(5):1448-69. PubMed ID: 15743188
[TBL] [Abstract][Full Text] [Related]
19. Novel inhibitors of Trypanosoma cruzi dihydrofolate reductase.
Zuccotto F; Zvelebil M; Brun R; Chowdhury SF; Di Lucrezia R; Leal I; Maes L; Ruiz-Perez LM; Gonzalez Pacanowska D; Gilbert IH
Eur J Med Chem; 2001 May; 36(5):395-405. PubMed ID: 11451529
[TBL] [Abstract][Full Text] [Related]
20. RASSE: a new method for structure-based drug design.
Luo Z; Wang R; Lai L
J Chem Inf Comput Sci; 1996; 36(6):1187-94. PubMed ID: 8941995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
